Biom'Up is a specialist in collagen-based absorbable medical devices for biosurgery and is developing a new generation haemostatic product, HEMOBLASTTM. The company also markets its proprietary products COVATM, COVAMESHTM and MATRITMBONE.
When ambition meets ambition
As haemostasis is a segment with a strong growth potential, Biom’Up wanted further develop the HEMOBLASTTM, particularly in the context of its clinical study conducted in Europe and North America.
We were convinced of the strong market potential of HEMOBLASTTM, which has an attractive product profile that addresses important unmet needs within the market of active haemostatic products. Moreover, the company is managed by a top level team that is highly experienced in the development and clinical evaluation of haemostatic products for surgery.
Together, we build a leading company
During our partnership, we supported the further development of HemoblastTM, in the context of its clinical study in Europe and North America. We were proud we could partner with this innovative and entrepreneurial company and, at the same time, could contribute to healthcare innovation by supporting the development of novel high-performing solutions that make life easier for surgeons and better for patients.
Mid October 2017, Biom’Up was successfully introduced on Euronext Paris.